DrugPatentWatch Database Preview
MOVANTIK Drug Profile
When do Movantik patents expire, and when can generic versions of Movantik launch?
Movantik is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and two patent family members in thirty-seven countries.
The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.
Summary for MOVANTIK
| International Patents: | 102 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 9 |
| Clinical Trials: | 11 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MOVANTIK |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MOVANTIK |
| DailyMed Link: | MOVANTIK at DailyMed |
Generic Entry Opportunity Date for MOVANTIK
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for MOVANTIK
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
US Patents and Regulatory Information for MOVANTIK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Pharms | MOVANTIK | naloxegol oxalate | TABLET;ORAL | 204760-001 | Sep 16, 2014 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Astrazeneca Pharms | MOVANTIK | naloxegol oxalate | TABLET;ORAL | 204760-001 | Sep 16, 2014 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Astrazeneca Pharms | MOVANTIK | naloxegol oxalate | TABLET;ORAL | 204760-001 | Sep 16, 2014 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MOVANTIK
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 12.5 mg and 25 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for MOVANTIK
Supplementary Protection Certificates for MOVANTIK
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0037 | France | ➤ Sign Up | PRODUCT NAME: NALOXEGOL OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'OXALATE DE NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141210 |
| 90027-7 | Sweden | ➤ Sign Up | PRODUCT NAME: NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141210 |
| 2015 00028 | Denmark | ➤ Sign Up | PRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141208 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
